Our observations that D-2-HG is required for tumor growth of cancer cells with IDH1/2 mutations suggest that inhibition of mutant IDH1/2 could be an attractive strategy for therapeutic treatment of cancers with IDH mutations. The gene discussed is IDH1; the disease is cancer.